Key clinical point: The primary endpoint was not met but lung function results were “clinically meaningful” in patients with systemic sclerosis (SSc).
Major finding: At week 48, 51.7% of tocilizumab- vs. 75.5% of placebo-treated SSc patients with interstitial lung disease experienced any decline in lung function (P = .003).
Study details: A phase 3, randomized, controlled trial (focuSSced) of 210 patients with early systemic sclerosis randomized to tocilizumab (n = 105) or placebo (n = 105).
Disclosures: Roche/Genentech sponsored the study. Dr. Khanna acts as a consultant to Roche/Genentech and eight other pharmaceutical companies. He owns stock in Eicos Sciences.
Khanna D et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):202-3. Abstract OP0245, doi: 10.1136/annrheumdis-2019-eular.2120.